Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Margaret Kaczor Andrew

Why IBD Stock Of The Day Penumbra, Up 27% This Year, Is Making A Comeback

Penumbra is Friday's IBD Stock Of The Day. After pulling back following a post-earnings breakout, Penumbra stock is eyeing two new entries.

Investors Business Daily

Why Dexcom Is On A Six-Day Losing Spree — But This Analyst Isn't Worried

Dexcom stock plunged to a four-month low Monday after the FDA issued a warning letter tied to inspections of two facilities in the U.S.

Investors Business Daily

Edwards Skids On Weak Expectations For Its Bread-And-Butter Moneymaker

Edwards Lifesciences stock fell Friday after the company said its TAVR segment will face numerous challenges in the fourth quarter.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Dexcom Pares Steep Losses Despite A Key Exec Departure Amid Stelo Launch

Dexcom stock closed in the red on Friday after the diabetes devices player beat third-quarter expectations and kept its outlook.

Investors Business Daily

ResMed Breaks Out As GLP-1 Drugs And Big Tech Help Drive A Quarterly Beat

ResMed stock broke out early Friday after the CPAP maker broadly beat third-quarter projections, shrugging off weight-loss drug worries.

Investors Business Daily

Will New 'Milestone' Glucose Monitor Help Dexcom Stock Bounce Back?

Dexcom launched its new continuous glucose monitor on Monday. But the move didn't help troubled Dexcom stock.

Investors Business Daily

As Diabetes Battle Heats Up, Spotlight Turns To Dexcom, Abbott

The diabetes donnybrook between Abbott Laboratories and Dexcom is poised to heat up — and could bolster both Abbott stock and Dexcom stock.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

How 'Megatrends' Like Weight-Loss Drugs And Smartwatches Are Bolstering ResMed

ResMed stock jumped Friday after crushing sales estimates and wiping out worries that weight-loss drugs would squeeze sleep apnea device sales.

Investors Business Daily

How The Weight-Loss Bonanza Prompted A ResMed Sell-Off — But Could Soon Drive Shares Higher

ResMed stock jumped Thursday after an analyst suggested the growing popularity of weight-loss drugs could drive use of its medical devices.

Investors Business Daily

Why Wall Street Got Even More Excited About The Glucose Monitor — And How Dexcom, Abbott Labs Stand To Benefit

Metabolic health is all the rage, helped by the advent of weight-loss drugs and continuous glucose monitors. Can they change disease forever?

Investors Business Daily

IBD Stock Of The Day Dexcom Lingers In Buy Zone As Diabetes Play Eyes Obesity Market

Dexcom is Wednesday's IBD Stock Of The Day. Dexcom stock is lingering in a buy zone, bolstered by U.S. clearance of a new body-worn glucose monitor.

Investors Business Daily

Dexcom Breaks Out As FDA Clears It To Enter A New Market: Obesity

Dexcom stock popped Wednesday after the FDA cleared its newest body-worn glucose monitor for people who don't require insulin treatment.

Investors Business Daily

People

Mike Matson

36 stories

Margaret Kaczor Andrew

12 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Investor Business Daily

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.